Compare VMI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMI | CYTK |
|---|---|---|
| Founded | 1946 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | VMI | CYTK |
|---|---|---|
| Price | $409.69 | $62.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $456.67 | $77.87 |
| AVG Volume (30 Days) | 154.4K | ★ 1.8M |
| Earning Date | 10-21-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.66 | N/A |
| Revenue | ★ $4,103,136,000.00 | $87,211,000.00 |
| Revenue This Year | $1.84 | $361.33 |
| Revenue Next Year | $4.07 | $65.14 |
| P/E Ratio | $35.82 | ★ N/A |
| Revenue Growth | 1.23 | ★ 2609.26 |
| 52 Week Low | $250.07 | $29.31 |
| 52 Week High | $432.69 | $69.33 |
| Indicator | VMI | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 48.91 |
| Support Level | $409.02 | $59.56 |
| Resistance Level | $432.69 | $67.26 |
| Average True Range (ATR) | 11.61 | 2.36 |
| MACD | 0.79 | -0.67 |
| Stochastic Oscillator | 49.46 | 33.98 |
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.